Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Asociación para Evitar la Ceguera en México

Overview

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema

A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up) pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein angiography was evaluated at months 1 and 3.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Diabetes Mellitus Type 2 Diabetic Macular Edema

Interventions

Intravitreal BevacizumabDRUG

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Macular edema involving the center of the macula demonstrated on OCT * Clear ocular media * Untreated patients * Older than 45 years * BCVA of the fellow eye at least 20/100 Exclusion Criteria: * Renal diabetic disease, uncontrolled hypertension or stroke history * Other ocular disease * Ocular surgery excepting uncomplicated phacoemulsification * History of photocoagulation (panretinal or focal) * History of another intravitreal treatment (like triamcinolone)

Locations (1)

Asociación para Evitar la Ceguera en México

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

BCVA

Fluorescein Angiography

Optical Coherence Tomography

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.